Menstrual Blood Stem Cells Studied in Novel Discovery

Researchers are saying that many types of human cells could be developed by a new type of stem cell that can be found in the blood that is shed during women’s menstrual cycles.

During the endometrial phase of the monthly menstrual cycle, a new uterine lining grows after the old one has been shed. Stem cells have been suspected to be one of the biological mechanisms that help the cells of the endometrium, or uterine lining, to regrow at such a fast rate.

Recent discoveries have proven that adult stem cells are found in large quantities within the uterine lining. However, harvesting those cells has been another issue.

Menstrual blood has provided an answer for this dilemma. Endometrial cells are found in the menstrual blood according to a study that was recently published in the Journal of Translational Medicine.

The study was conducted using menstrual blood taken from two women, at the private research institute, the Bio-Communications Research Institute, in Wichita, Kansas. Xiaolong Meng led a team that studied the cells. The collaborated with Medistem Laboratories, Inc. (OTC BB:MDSM.OBNews) (Frankfurt:S2U.FNews), who own the intellectual property rights for the discovery.

With a behavior analogous to that of stem cells, the team found the following similarities:

The team says they found cells that behaved very much like stem cells:

– They showed characteristic cell surfaces of stem cells.

– Given the right environment, the cells were able to differentiate into many different cell types.

– They easily copied themselves.

In contrast to mesenchymal cells, which are found in umbilical cord blood, the menstrual cells reproduced more rapidly. They doubled about every 19.4 hours.

Lung, heart, and liver cells, were only 3 of at least 9 different cell types that were developed from the menstrual blood cells by the research team.

Many possible uses could be in store for the cells type once cultured at a large scale. The researchers are calling the cells endometrial regenerative cells.

“We have many problems with our current methods of stem cell therapy, like those taken from bone marrow. They may be rejected by the recipient and/or have limited potential to generate new tissue,” said Meng.

“Now we’ve found a possible new way to overcome these difficulties by using cells from menstrual blood.”

Stem Cells Discovered in Menstrual Blood

A research team from Wichita, Kansas has made a novel discovery involving adult stem cells that have been derived from menstrual blood.

To prepare itself to take care of a fertilized egg, the uterine lining is rebuilt each month after it has been shed to provide a new medium for egg development. The process is impressive, with a new 5 millimeter thick lining developed in only 7 days. This is accomplished by literally, growing billions of cells.

Adult stem cells are found in abundance in the endometrium, or uterine lining. But despite the rich source, actually harvesting the cells is a similar process as is involved with other sources such as bone marrow: the process is invasive.

The research team in Kansas has discovered that menstrual blood contains these endometrial stem cells as well.

The cells show characteristic cell surfaces of stem cells, given the right environment, can differentiate into at least 9 different cell types, and can create copies of themselves without differentiating. These are all qualities that can be associated with existing stem cells as well.

Menstrual blood was taken form two women for the teams research purposes. Xiaolong Meng and his team conducted the study at a private research institute in Wichita, Kansas, called the Bio-Communications Research Institute. The team collaborated with Medistem Laboratories, Inc. (OTC BB:MDSM.OB – News) (Frankfurt:S2U.F – News in making the discovery. Their paper which is titled, “Endometrial Regenerative Cells: A Novel Stem Cell Population”, has been published in the Journal of Translational Medicine. The paper can be viewed at www.translational-medicine.com/content/5/1/57

Medistem Laboratories, Inc. own the intellectual property rights to the discovery.

The menstrual blood derived cells doubled every 19.4 hours, marking a proliferation rate higher than the mesenchymal stem cells which are derived from cord blood. The researchers say that a few embryonic stem cell markers were observed in addition to the adult stem cell markers that were exhibited by the cells. One particular embryonic stem cell marker called Oct-4, which is considered a “master” marker, was observed.

Muscle, bone, fat, and nerve cells were among the nine different cell types that were created using the menstrual blood derived cells.

Medistem Announces Discovery: Menstrual Blood Yields Novel Stem Cell Population

A paper describing a novel stem cell population derived from menstrual blood has been published by Medistem Laboratories, Inc. (OTC BB:MDSM.OBNews) (Frankfurt:S2U.FNews) in collaboration with the Bio-Communications Research Institute in Wichita, Kansas, the University of Alberta, and the University of Western Ontario. The Journal of Translational Medicine has published the paper which is titled, “Endometrial Regenerative Cells: A Novel Stem Cell Population”. The publication is free to read at www.translational-medicine.com/content/5/1/57

“I view the discovery of the Endometrial Regenerative Cell (ERC) as a great step forward in providing an ethical, easily accessible, and potentially highly useful adult stem cell for treatment of numerous degenerative conditions,” said Dr. Xiaolong Meng, head of the research team. He continued, “ERC cells can be converted into basically all the major tissues of the body, including the liver, lung, pancreas, brain, heart, blood vessel, and muscle. Additionally, these cells produce 100,000 times the number of growth factors found in cord blood, opening the door to numerous regenerative applications.”

The study has exhibited that menstrual blood stem cells possess special cellular and molecular characteristics. This is the first publication in a peer-reviewed medical journal demonstrating these facts.

“The ability to take a cell and differentiate it into the tissue type needed by the body creates a world of opportunity in the world of organ and tissue regeneration,” said Neil Riordan, PhD, President and CEO of Medistem. He added, “With IP filed around the cell line, we have begun taking the next steps in the commercialization process. Currently, our collaborators at Western Ontario, Alberta, and the Bio-Communications Research Institute are doing a series of pre-clinical studies to establish efficacy data in a variety of indications. The indications currently being assessed include diabetes, liver cirrhosis, lung fibrosis, organ rejection, and multiple sclerosis. Should the data gathered prove strong in one or all the indications the next step will be to file INDs with the FDA and move into clinical trials,” said Riordan.

About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. Medistem’s primary focus is drug discovery and development, however, Medistem also outlicenses proprietary technology from their growing intellectual property portfolio to commercial entities in markets where stem cell administration is permissible. Medistem believes it is well positioned to be a leading developer of adult stem cell products given its licensee relationships and collaborative efforts with respected institutions.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company’s products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company’s actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company’s quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.